Erik Schwiebert, PhD

Erik Schwiebert, PhD, leads all Station 41 programs. He is focused on new early-stage, mid-stage, and later stage therapeutics discovery and development projects identified within Southern Research and its allied institution, the University of Alabama at Birmingham. Erik holds a PhD in cell biology and physiology in health and disease from Dartmouth College’s Medical School (now the Geisel School of Medicine) as well as a postdoctoral fellowship in cell physiology from The Johns Hopkins University School of Medicine. He has held multiple leadership positions in both academic and industry settings, including founding DiscoveryBioMed, Inc.—a life sciences and biotechnology company that gave rise recently to AeroNeph Therapeutics, Inc. DiscoveryBioMed’s human cell models and assays that underpinned its CRO services business were acquired recently by Eurofins Discovery Panlabs and integrated into its Translational Biology Center of Excellence.